Medicines List

Description

Fluidoro, which contains the active substance prasugrel, belongs to a group of medicines called platelet antiplatelet agents.
Fluidoro inhibits the accumulation of platelets and thus reduces the risk of blood clots.

Indications

Fluidoro co-administered with acetylsalicylic acid (ASA) has been shown to prevent atherothrombotic events in adult patients with acute coronary syndrome (eg unstable angina, non-ST-segment elevation myocardial infarction [UA/NSTEMI] or myocardial infarction) of ST [STEMI] undergoing primary or delayed percutaneous coronary intervention (PCI).

Subject to medical prescription.

Concentration and pharmaceutical form: 10 mg film-coated tablets

Description

Zornichka belongs to group of medicines called thiazide diuretics. Thiazide diuretics help the body excrete excess fluid by stimulating the kidneys to excrete more urine.

Indications

Zornichka is indicated for:
– treatment of arterial hypertension, essential or nephrogenic, or isolated systolic hypertension. Zornichka can be used alone or in combination with other antihypertensive drugs;
– treatment of mild to moderate stable, chronic heart failure (NYHA functional class II-III) with stagnation;
– welling of specific origin:
— ascites due to cirrhosis of the liver in stable patients under close supervision;
— edema due to nephrotic syndrome, acute glomerulonephritis and chronic renal failure (with creatinine clearance > 30ml/min);
— corticosteroid and estrogen therapy.
– nephrogenic insipidus diabetes (Diabetes Insipidus).

Subject to medical prescription.

Concentration and pharmaceutical form: 12.5 mg, 25 mg tablets

Description

PlaquEx Combi contains clopidogrel and acetylsalicylic acid (ASA) and belongs to a group of medicines called antiplatelet medicinal products. It prevents the clumping of the platelets in the blood vessels and reduces the chances of blood clots forming.

Indications

PlaquEx Combi is indicated for the secondary prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid (ASA). PlaquEx Combi is a fixed-dose combination medicinal product for continuation of therapy in:
– non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary intervention;
– ST segment elevation acute myocardial infarction in medically treated patients eligible for thrombolytic therapy.

Subject to medical prescription.

Concentration and pharmaceutical form: 75 mg/75 mg hard capsules

Description

Ivabenor contains ivabradine. It mainly works by reducing the heart rate by a few beats per minute. This lowers the heart’s need for oxygen especially in situations when an angina attack is more likely to happen. Ivabenor thereby helps to control and reduce the number of angina attacks.

Indications

Symptomatic treatment of chronic stable angina pectoris
Ivabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease in adults with normal sinus rhythm and heart rate ≥ 70 bpm.
Ivabradine is indicated:
– in adults unable to tolerate or with a contraindication to the use of beta-blockers;
– in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose.

Treatment of chronic heart failure
Ivabradine is indicated in chronic heart failure II to IV class (according to NYHA classification) with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ≥ 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated.

Subject to medical prescription.

Concentration and pharmaceutical form: 5 mg, 7.5 mg film-coated tablets